97839-99-1

Usage

Uses

It is employed as intermediate for pharmaceutical.

InChI:InChI=1/C11H14ClNO/c12-9-1-3-10(4-2-9)14-11-5-7-13-8-6-11/h1-4,11,13H,5-8H2

Upstream product

• 333954-83-9 tert-butyl 4-(4-chlorophenoxy)piperidine-1-carboxylate 
• 106-48-9 4-chloro-phenol 
• 28231-84-7 4-(4-chlorophenoxy)pyridine 
• 626-61-9 4-Chloropyridine 

Downstream Products

• 1304781-43-8 benzo[d]isoxazol-3-yl-(4-(4-chlorophenoxy)piperidin-1-yl)methanone 
• 1233228-06-2 1-(4-chloro-5-methoxy-2-nitro-phenoxy)-3-[4-(4-chloro-phenoxy)-piperidin-1-yl]-propan-2-ol 
• 1233227-97-8 1-[3-(4-Chloro-5-methoxy-2-nitro-phenoxy)-propyl]-4-(4-chloro-phenoxy)-piperidine 
• 1219625-79-2 1-{2-[4-(4-chlorophenoxy)piperidin-1-yl]-2-oxoethyl}-3,3-diphenylpiperidin-2-one 
• 1174043-28-7 C₂₆H₂₃ClN₄O₃ 
• 210917-87-6 4-(4-chlorophenoxy)piperidine-1-sulfonyl chloride 
• 1088900-88-2 4-(4-chlorophenoxy)-N-(2-methylbut-3-yn-2-yl)piperidine-1-sulfonamide 
• 296765-79-2 {2-[4-(4-Chlorophenoxy)piperidine-1-sulfonyl]phenyl}acetic acid 
• 875211-48-6 5-{2-[4-(4-chloro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-3H-benzooxazol-2-one 

Relevant academic research and scientific papers

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A- II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a and R4aa and R4b are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS

The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS

The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

ANTIPARASITIC TERPENE ALKALOIDS

The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

Oxamides as novel NR2B selective NMDA receptor antagonists

A novel series of oxamides derived from indole-2-carboxamides was identified as potent NR2B selective NMDA receptor antagonists. Several members of this group showed good analgesic activity in the mouse formalin test.

Analgesic substituted-1-aminoalkylamino-4-aryloxypiperidines

There are described analgesic substituted-1-aminoalkylamino-4-aryloxypiperidines of the formula STR1 where X is hydrogen, loweralkyl, CF3, acetyl or halogen; n is 1 or 2; R1 is H2 or oxygen; R2 is H, loweralkyl